It is time to consider a new topical algorithm for psoriasis
- PMID: 37813190
- DOI: 10.1016/j.jaad.2023.07.1048
It is time to consider a new topical algorithm for psoriasis
Keywords: corticosteroids; psoriasis; roflumilast cream; tapinarof cream.
Conflict of interest statement
Conflicts of interest Author Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, DermTech, Dr. Reddy’s Laboratories, Eli Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health. Authors Engel, Smith, and Javadi have no conflicts of interest to declare
Comment in
-
Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis".J Am Acad Dermatol. 2024 Feb;90(2):e83. doi: 10.1016/j.jaad.2023.08.109. Epub 2023 Oct 30. J Am Acad Dermatol. 2024. PMID: 37821054 No abstract available.
Comment on
-
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.J Am Acad Dermatol. 2021 Feb;84(2):432-470. doi: 10.1016/j.jaad.2020.07.087. Epub 2020 Jul 30. J Am Acad Dermatol. 2021. PMID: 32738429
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
